A study comparing Opdivo to dacarbazine chemotherapy in treatment naïve advanced melanoma patients marks first PD-1 immune checkpoint inhibitor to demonstrate a survival benefit in a phase III trial.
The Brigham & Women's Hospital has halted a controversial study that combined power morcellators with “containment bags” intended to capture tissue during minimally invasive gynecological surgery.
The power morcellator should no longer be used for hysterectomies or fibroid removal in the vast majority of women getting these procedures, FDA declared in a highly anticipated guidance document Nov. 24.
TAPIMMUNE Inc. and the Vaccine & Gene Therapy Institute of Florida formed a partnership to advance TapImmune's cancer vaccines into phase II clinical trials for the treatment of breast and ovarian cancers.
DANA-FARBER CANCER INSTITUTE and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer.
NYU LANGONE Medical Center and Lutheran Medical Center will create a clinically integrated health care provider network for the New York metropolitan area.
MERCK KGAA and Pfizer Inc. will co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple tumor types.\
SUSAN MAYNE was appointed director of the FDA Center for Food Safety and Applied Nutrition.
BERT VOGELSTEIN was awarded the 2014 Warren Triennial Prize by Massachusetts General Hospital.
THE BARBARA ANN KARMANOS CANCER INSTITUTE was honored by the Michigan Cancer Consortium with the 2014 Spirit of Collaboration Award for its Jewish Women's Health Project; and also received an Honorable Mention for its Harley Men's Health Event.